# Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs

L.L. Green, M.C. Hardy, C.E. Maynard-Currie, H. Tsuda, D.M. Louie, M.J. Mendez, H. Abderrahim, M. Noguchi, D.H. Smith, Y. Zeng, N.E. David, H. Sasai, D. Garza, D.G. Brenner, J.F. Hales, R.P. McGuinness, D.J. Capon, S. Klapholz & A. Jakobovits

We describe a strategy for producing human monoclonal antibodies in mice by introducing large segments of the human heavy and  $\kappa$  light chain loci contained on yeast artificial chromosomes into the mouse germline. Such mice produce a diverse repertoire of human heavy and light chains, and upon immunization with tetanus toxin have been used to derive antigen-specific, fully human monoclonal antibodies. Breeding such animals with mice engineered by gene targeting to be deficient in mouse immunoglobulin (Ig) production has led to a mouse strain in which high levels of antibodies are produced, mostly comprised of both human heavy and light chains. These strains should provide insight into the adoptive human antibody response and permit the development of fully human monoclonal antibodies with therapeutic potential.

Cell Genesys, Inc., 322 Lakeside Drive, Foster City, California 94404, USA

Correspondence should be addressed to A.J. Fully human antibodies, with lower immunogenicity and more desirable pharmacological properties than engineered mouse antibodies, may fulfill the enormous potential for monoclonal antibodies (mAbs) in treating human disease. As the use of human B cells as a source of rearranged human antibody genes may limit the generation of therapeutically useful specificities, particularly when the target antigen is of human origin, attention has focused on the use of transgenic mice bearing unrearranged human immunoglobulin (Ig) genes to exploit the adaptive immune response of the mouse<sup>1-6</sup>. So far, however, the ability to generate antigen-specific human antibodies in mice has proved elusive. Mice bearing minigene constructs rearrange and express human Ig genes, but the highly skewed or aberrant, fetal-like human Ig repertoires produced in such mice, and the low expression of human Ig relative to endogenous mouse Ig<sup>2-4</sup>, has precluded the demonstration of antigen-specific human antibodies. Hence the need for large germline segments of human Ig genes with larger variable gene repertoire and critical regulatory elements to achieve normal levels of expression and diversity is suggested.

Here we describe a novel strategy which permits the generation of mouse hybridomas making antigen-specific human mAbs and the creation of a mouse strain in which the majority of Ig produced are fully human. Using technology we have recently developed<sup>7</sup>, yeast artificial chromosomes (YACs) carrying large segments of the human heavy and  $\kappa$  chain loci have been introduced into the mouse germline via fusion of yeast spheroplasts with mouse embryonic stem (ES) cells. These mice produce a broad adult-like repertoire of human Ig and are capable of giving rise to antigen-specific human mAbs upon


immunization. Breeding of such mice with those whose heavy and  $\kappa$  genes have been inactivated by gene targeting has led to the creation of a strain which primarily produces fully human antibodies. Such mice may be exploited to elucidate the nature of the human humoral immune response upon infection or immunization, and to develop fully human therapeutic mAbs.

# Human Ig YACs in ES cells and mice

YACs containing sequences from the human heavy and kappa chain loci (Fig. 1) were shown to be in intact, germline configuration (M.J.M. *et al.*, manuscript in preparation). The cloned heavy chain YAC (220 kb insert) contains the mu ( $\mu$ ) and delta ( $\delta$ ) constant (C) regions, all six functional joining (J) regions, the major diversity (D) cluster, the intronic enhancer and five most proximal variable (V) genes from four V<sub>H</sub> families: V<sub>VP</sub> V<sub>L2</sub>, V<sub>L3</sub>, V<sub>IV4</sub> and V<sub>IL5</sub> (Fig. 1)<sup>8.9</sup>. The cloned  $\kappa$  YAC (170 kb insert) contains the  $\kappa$  deleting element (Kde), the intronic and 3' enhancers, the C<sub>k</sub> region, all five functional J regions and the three most proximal V<sub>k</sub> regions in the B cluster (B1, B2, B3) (Fig. 1)<sup>10</sup>. A human HPRT selectable marker<sup>11</sup> was targeted into the right vector arm of each YAC (Fig. 1; M.J.M. *et al.*, manuscript in preparation).

HPRT-targeted human heavy (yH1) and  $\kappa$  (yK1) chain YACs were introduced into the HPRT-deficient ES cell line E14.TG3B1 (H.T. *et al.*, manuscript in preparation) by yeast spheroplast-ES cell fusion<sup>7</sup>. Seven and 11 HPRT<sup>+</sup>-ES clones obtained by fusion of yH1- or yK1-containing yeast, respectively, were analysed by Southern blotting for the integrity of the YACs. Five yH1-containing clones (2B, 2C, 3A, 125A, 125E) and 10 yK1-containing clones contained all *Hin*dIII fragments detected by probes

# article






Fig. 1 Characterization of human heavy and  $\kappa$  light chain YACs integrated in ES cells and transgenic mice. Schematic representations of the human heavy (yH1) and kappa (yK1) YACs, retrofitted with a HPRT minigene, are shown above *a* and *c*, respectively. The locations of specific lg regions are indicated along with YAC vector elements: **b**, telomere; **Q**, centromere; **E**, *Eco*RI cloning site and yeast selectable markers, TRP1 and URA3. (YAC arms are not shown to scale.) *a*, *b*, Southern blot analysis of *Hin*dlll-digested DNA (10 µg) from: *a*, yH1-containing ES clones: 2B, 2C, 3A, 3B, 5C, 125A and 125E, probed with human Cµ and mouse Cx (*a*1) and yeast Ty sequences (*a*2); *Hin*dlll-digested yH1, embedded in agarose, was used in *a*, resulting in slightly slower-migrating fragments than the corresponding fragments from yH1 in ES cells prepared in solution. *b*, mice (2 individual offspring from each strain) generated from clones: 2B, 3A, 5C, 125A, and yH1-containing haploid yeast DNA (a= 40 ng and b=20 ng corresponding to 2 and 1 YAC DNA copies, respectively). Probes: J<sub>H</sub> (*b*1), D (*b*2), V<sub>W</sub> (*b*3, the band detected above the 8 kb V<sub>W</sub> fragment in the 2B lane represents a partial digest), V<sub>H</sub> (*b*4) and yeast Ty sequences (*b*5). *c*, *d*, Southern blot analysis of *Hin*dlll-digested DNA (10 µg) from: *c*, unmodified E14.TG3B1 (3B1) and yK1-containing ES clones: 4.4, 5.2, 8.2A, 9.2C, 9.2E, 9.2H, 10.2A, 10.2B and 10.2CA and *d*, mice (2 individual offspring, except 9.2E) generated from clones 8.2A, 9.2C, 9.2E and 10.2B, yK1-containing haploid yeast DNA (a=10 ng, b=20 ng and c=40 ng (when shown), representing 0.5, 1 and 2 YAC DNA copies, respectively). Probes: J<sub>w</sub> and mouse C<sub>x</sub> (*c*, *d*1), B1 (*d*2), B2 (*d*3), B3 (*d*4) and yeast Ty sequences (*c*2, *d*5). Fragment sizes (in kb) are indicated e. Identification by PCR analysis of HuAb mice (1, 3 and 10) in a mouse litter (1-12) derived from the mating of yH1-and yK1-containing mice. Specific human heavy chain (D, 230 bp), x chain (J<sub>w</sub> 860 bp) an

# Table 1 Structural integrity of human heavy and $\kappa$ light chain YACs in ES clones and their expression in mice

a				_						
yH1 ES Cell Clone	Cδ 7.8 kb	Сµ 11 kb	]Н 10 кр	D 9.7, 8.5, 7 kb	V <sub>VI</sub> ~ 28 kb	VI >12, 1.7 kb	VIV 8 kb	VП 4.8 kb	Yeast Genomic Sequences	YAC copy number
2B	+	+	+	+	+	+	+	+	-	1
2C	+	+	+	+	+	+	+	+	+	2
125A	+	+	+	+	+	+	+	+	+	1
125E	+	+	+	+	+	+	+	+		1
3A	+	+	+	+	+	+	+	+	+	_ <u>_</u>
3B	+	+	+	9.7 kb 8.5 kb	+	+	+	+	<b>,</b> +	~8
20										

yK1 ES Cell Clone	Kde 2.5 kb	С <sub>К</sub> 5.8 kb	J <sub>K</sub> 5 kb	B3 4.8 kb	B2 5.1 kb	B1 2.8 kb	Yeast Genomic Sequences	YAC copy number
4.4	+	+	5.5 kb	4.7 kb	4.9 kb	+	+	1
5.2	+	+	+	+	+	+		1
8.2A	+	+	+	+	+	+		1
9.2E	+	+	+	+	+	+	+	2
9.2C	+	+	+	+	+	+	· · ·	1
10.2B	+	+	+	+	+	+	+	1
9.2H	+	+	+	+	+	+		~3
9.2F	+	+	+	+	ND	+		-
10.2C	+	+	+	+	ND	+	1	1
10.2A	+	+	+	+	+	+	+	2
10.2CA	+	+	+	+	+ 1	+		2

	h Heavy Chain			Huma	n Kappa Chain	
yH1 Mouse Clone	yH1 Copy Number	hµ Expression (µg/ml)		yK1 Mouse Clone	yK1 Copy Number	h <sub>κ</sub> Expression (µg/ml)
*3B	~8	3.8	1 F	5.2	1	30.0
125A	1	0.9	1 [	10.2B		27.5
5C	1	0.8	1 1	9.2C	1	17.7
2B	1	0.7	1 [	*9.2H	-3	15.5
3A	1	0.4	ו ר	*9.2F	1 1	11.0
2C	2	0.4		9.2E	2	10.5
*125E	1	0.2	1 1	*10.2C	1	8.1
Control	0	0.0		8.2A	1 1	8.0
		-	· [	4.4	1	0.0
			[	Control	0	0.0

a, b, HPRT\*-ES clones, generated by fusion of ES cells with yH1- (a) or yK1- (b) containing yeast spheroplasts, were analysed for the presence of human heavy or  $\kappa$  chain-specific sequences, and yeast genomic sequences (see Methodology). The presence of the expected fragment sizes for the specific probe (as shown), and of varied levels of yeast genomic sequences are indicated as '+'. Altered-sized fragments are indicated. In the case of yH1- ES clone 3B, the 7 kb doublet from the D region was deleted. ND-not determined. *c*, *d*, Detection of human heavy and  $\kappa$  chains in mouse sera. Serum samples derived from yH1- (c) or yK1- (d) containing transgenic or chimaeric (\*) mice, from the indicated ES clones, or non-transgenic littermate mice (control), were analysed by ELISA for h $\mu$  or h $\kappa$ . Shown are representative serum titrations for individual mice.

Fig. 2 Surface expression of human  $\mu$  and  $\kappa$  chains on yH1- and yK1- containing mouse B cells. Blood or spleen lymphocytes derived from yH1-(a), yK1-(b,c,d) and yH1;yK1- (HuAb) (e) containing mouse strains or control mice (129xC57BI/6:A1, B1, C1, D1, E1) were analysed by 2- or 3-colour flow cytometry for surface expression of human µ or κ chains, using antibodies to the B cell-specific marker B220 in combination with anti-human  $\mu$  or  $\kappa$ , and anti-mouse  $\mu$ ,  $\kappa$  or  $\lambda$ , respectively. The net percentage of positively-stained cells (obtained by subtracting the background staining of each control) is shown in each quadrant. a, Blood samples from control (A1), or yH1-mice generated from clones 2B (A2), 5C (A3) and 125A (A4), were gated on B220<sup>+</sup> cells and assayed for migM<sup>a</sup> and migM<sup>b</sup>, and hu. b, Spleen lymphocytes from control (B1) or yK1-containing mice: 9.2C (B2), 8.2A (B3), and 10.2B (B4) were assayed for B220 and hk. c, d, Spleen lymphocytes from control (C1, D1) or yK1containing mice 8.2A (C2, D2), gated on B220\* cells and assayed for expression of hk and mk (c) or gated on B220<sup>+</sup> cells and assayed for expression of hk and m $\lambda$  (d). The percentage of m\u03c8\* B cells was similar (approximately 6%) in D1 and D2. e, Blood samples derived from control (E1) or HuAb strains (E2: 8.2A;125A, E3: 8.2A;5C) were analysed by 3-colour flow cytometry for surface expression of human  $\mu$  and  $\kappa$  on B220\* cells. The net percentage of positively-stained cells is shown in each quadrant. The FACS profiles shown are representative of five experiments performed on these strains. Similar analysis indicated the presence of hu\*/hk\* populations in other HuAb strains: 8.2A;2B (0.27%), 9.2C; 125A (0.13%) and 9.2C;2B (0.11%).


spanning the entire respective inserts (Fig. 1, Table 1). Deletions within the D or V<sub>11</sub> regions of yH1 were detected in clones 3B and 5C, respectively, and altered J $\kappa$ , B3 and B2 fragments of yK1 were detected in clone 4.4. All clones retained the HPRT-containing right vector arm. All yK1-containing clones and four out of seven yH1-containing clones (2C, 3A, 3B, 125A) retained an intact left arm (data not shown). All clones contained a single YAC integration except 2C and 3B (yH1) and 9.2E, 9.2H, 10.2A and 10.2CA (yK1). Hybridization with yeast repetitive probes (Ty, Y',  $\delta$ , rRNA) demonstrated the presence of varying amounts of yeast genomic sequences in 4 yH1 ES clones (2C, 125A, 3A, 3B) and 5 yK1 clones (4.4, 9.2E, 10.2B, 10.2A, 10.2CA) and their absence in the remaining ES clones (Fig. 1, Table 1).

The integrity of introduced YACs was further assessed by pulsed-field gel electrophoresis following digestion with Notl (a site absent in yH1) or Sfil (a site occurring once in yK1, generating a 105 kb fragment containing the Kde-B1 region). A single, unique fragment hybridizing to multiple yH1 or yK1 specific probes was demonstrated in 5 yH1 (2B, 3A, 5C, 125A and 125E) and in 6 yK1 (5.2, 8.2A, 9.2C, 9.2F, 10.2B, 10.2C) ES clones (data not shown; M.J.M. et al., manuscript in preparation). Together, these results strongly suggest that these clones contain a single, structurally intact YAC.

YAC-containing chimaeric mice were generated from 7 yH1 and 9 yK1 ES clones. Approximately 50% of their agouti offspring contained in their germline the respective YAC and yeast sequences (when present) in unaltered form (Fig. 1).

# Human Ig production in mice

The expression of the human heavy mu  $(h\mu)$  and kappa  $(h\kappa)$  chains on B cells and in serum of yH1- and yK1- containing mice was investigated by flow cytometry and



#### Table 2 Repertoire analysis of human heavy chain transcripts expressed in transgenic mice

1	-				n			3					
1000 40	in Frame	Vu4	GCGAGAGA	TCG	<u>D</u> N1	GGGTATAG	TGGGAGCCC			ACTTTGACTACT	GOGGCCAG	GGAACCO	TOGTCACCGTCTCCT
13	out	VH4 VH4	GCGAGAGA	GGA	N1	GGTATAGCAGLOGC	CGGTACA	J3					TGGTCACCGTCTCTT
46	in		GCAA	GGA	21/9	TTACTATGATAGTAGTGGTTATTAC	TGAGCATTACT						TOGTCACCGTCTCCT
	in	V <sub>H</sub> 6	GCGAGA	GGG	21/3 XP4	CGATTTTTGGAGTGGTTA	AAGAGGTCC	J6	#30#30#30#30				COGTCACCOTCTCCT
50		V <sub>H</sub> 1	GCGAGAGA	GAGGC	M1	GTATAACTGGAACTAC	GGAG	J6					ACGGTCACCGTCTCCT
55	in	V <sub>H</sub> 1		GAUGC	M1	GTATAACTGGAACTAC	GGAG	J5					TOGTCACCGTCTCCT
56	in	V <sub>H</sub> 6	GCA		XP1		CCCCTGAT	J3					ATGGTCACCGTCTCTT
65	in*	VH1	GCG	GTCC		GTATTACGATATTTTGACTGGTTA	CCCCIGAT	J3					ATGGTCACCGTCTCTT
73	in	V <sub>H</sub> 4	GCG	с	K1	GTGGATATAGTGGCTACGAT	CGGG	J3 J4					TGGTCACCGTCGCCT
BO	out	V <sub>H</sub> 4	GCGAGAGA		M1	ACTGGAACTAC							CTGGTCACCGTCTCCT
85	in	V <sub>H</sub> 1	GCGAG	GOGGGG	N1	TAGCAGtgGCTGGTAC	CTGA	J4					CTGGTCACCGgCTCCT
67	in	VH1	GCGAGAGAG		N4	TATAGCAGCTCGTC		J					CTGGTCgCCcTCTCCT
89	in	VHI	GCGAGA	AGGGCG	N1	AGCAGCAGCT	TCTC	J4					
90	in	V <sub>H</sub> 1	GCGAGAG	GAGGGGCCCATT	LR2	GTGGTGGTgaCTGCT	CTACGTAC	34					CTGGTCACCGTCTCCT
.97	in	V <sub>H</sub> 6	GCAAGA		LR2	GTGGGAGCT	ACCCT	J4		CTTTGACTACT			CTGGTCACCGTCTCCT
.98	out	V <sub>H</sub> 6	GCAAGAGA	TGAGGGGA	λ4	TGACTACAGTAAC	cc	J4					CTOGTCACCGTCTCCT
100	in	V <sub>H</sub> 6	GCAAGAGA	GGGAGCAGTGGC	21/9	TGGTTATTAC		Je					ACGGTCACCGTCTCCT
102	in	V <sub>H</sub> 6	GCAAGAGA		M1	TAACTGGAAC	ACGT	Je	CTACTACO				ACGGTCACCGTCTCCT
104	in	V <sub>H</sub> 6	GCA		<b>A</b> 1	GACTACAGTAACT		J4		TIGACIAC	GGGGCCAL	300000000	CTGGTCACCGTCTCCT
						C	¥		¥-	Ver	Total		Ruman PDL(ref.1)
	713		CDR3	774		c	VII	ÂIA	٧Ţ	AAI	Total		
Lone			CTR3 DRGIVGAHFDY		LVTVSS			0 <b>AIA</b>	¥r 1	0	1	(1%)	18
10000.				WGQG1	LVTVSS		0				1 1	(1%)	1%
1008 40 46	AR		DRGIVGANFDY	WGQG1 YFDY WGQG1			0	0		0	1		1% 0% 9.1%
1000 0 40 46 50	AR AI AR		DRGIVGAHFDY THIVVVITEHY	WGQG1 YFDY WGQG1 YYYQMDV WGQG1	LVTVSS	J <sub>1</sub> J <sub>2</sub> J <sub>3</sub>	0	0	1	0	1 1	(1%)	1%
1000	AR AI AR AR		DRGIVGAHFDY TMIVVVITEHY GRFLEWLKRSY ERRITGTTEYY	WGQG'I YFDY WGQG'I YYYGMDV WGQG'I YYGMDV WGQG'I	LVTVSS TVTVSS TVTVSS	J1 J2 J3 J4	0 0 0 0 0	0	1 1 7	0 0 3	1 1 15	(1%) (18%)	1% 0% 9.1%
1000 40 46 50 55 56	AR AI AR AR AG		DRGIVGAHFDY TMIVVVITEHY GRFLEWLKRSY ERRITGTTEYY ITGTNWFDP	WGQG7 YFDY WGQG7 YYYGMDV WGQG7 YYGMDV WGQG7 WGQG7	LVTVSS TVTVSS TVTVSS LVTVSS	31 32 33 34 35	0 0 0 0 0 0	0 0 5 8	1 1 7 16	0 0 3 21	1 1 15	(1%) (18%) (54%)	1% 0% 9.1% 52.5%
1000	AR AI AR AR AG AR		DRGIVGANFDY TMIVVVITENY GRFLEWLKRSY ERRITGTTEYY ITGTNWFDP GYSGYDAFDI	WGQG7 YPDY WGQG7 YYYGMDV WGQG7 YYGMDV WGQG7 WGQG7 WGQG7	LVTVSS TVTVSS TVTVSS LVTVSS MVTVSS	J1 J2 J3 J4	0 0 0 0 0 0	0 0 5 8 0	1 1 7 16 3	0 0 3 21 1	1 1 15 45 4	(1%) (18%) (54%) (5%)	1% 0% 9.1% 52.5% 15.2%
1000 0 40 46 50 55 56 73 85	AR AI AR AR AG AR AR		DRGIVGAHFDY TMIVVVITEHY GRFLEWLKRSY ERRITGTTEYY ITGTNWFDP GYSGYDAFDI GGSSGWYLIDY	WGQGT YFDY WGQGT YYYGMDV WGQGT YYGMDV WGQGT WGQGT WGQGT WGQGT	LVTVSS TVTVSS TVTVSS LVTVSS MVTVSS LVTVSS	3 <u>1</u> 32 33 34 35 35 36	0 0 0 0 0 0	0 0 5 8 0 3	1 1 7 16 3 7	0 0 3 21 1	1 1 15 45 4	(1%) (18%) (54%) (5%)	1% 0% 9.1% 52.5% 15.2% 22.2%
1000 10 40 46 50 55 56 73 85 85 87	AR AI AR AR AG AR AR AR AR		DRGIVGANFDY TMIVVVITEHY GRFLEWLKRSY ERRITGTTEYY ITGTNWFDP GYSGYDAFDI GGSSGWYLIDY EYSSSSFDY	WGQG1 YPDY WGQG3 YYYGMDV WGQG3 YYGMDV WGQG3 WGQG3 WGQG3 WGQG3 WGQG3	LVTVSS TVTVSS TVTVSS LVTVSS MVTVSS LVTVSS LVTVSS	31 32 33 34 35	0 0 0 0 0 0	0 0 5 8 0	1 1 7 16 3	0 0 3 21 1 7	1 15 45 4 17	(1%) (18%) (54%) (5%) (21%)	1% 0% 9.1% 52.5% 15.2% 22.2%
1004 40 46 50 55 56 73 85 85 87 89	AR AI AR AG AR AR AR AR		DRGIVGAHFDY TMIVVVITEHY GRFLEWLKRSY ERRITGTTEYY ITGTNWFDP GYSGYDAFDI GGSSGWYLIDY EYSSSFDY RASSSFSFDY	YPDY WGQG1 YPDY WGQG1 YYGMDV WGQG1 YYGMDV WGQG1 WGQG1 WGQG1 WGQG1 WGQG1	LVTVSS TVTVSS TVTVSS LVTVSS MVTVSS LVTVSS LVTGSS LVTGSS LVALSS	3 <u>1</u> 32 33 34 35 35 36	0 0 0 0 0 0	0 0 5 8 0 3	1 1 7 16 3 7	0 0 3 21 1 7	1 15 45 4 17	(1%) (18%) (54%) (5%) (21%)	1% 0% 9.1% 52.5% 15.2% 22.2%
1000 40 40 46 50 55 56 73 85 87 89 90	AR AI AR AR AG AR AR AR AR		DRGIVGANFDY TMIVVVITEHY GRFLEWLKRSY ERRITGTTEYY ITGTNWFDP GYSGYDAFDI GGSSGWYLIDY EYSSSSFDY	YEDY WGQG1 YEDY WGQG3 YYYGMDV WGQG3 YYYGMDV WGQG3 WGQG3 WGQG3 WGQG3 WGQG3 WGQG3 WGQG3	LVTVSS TVTVSS TVTVSS LVTVSS MVTVSS LVTVSS LVTVSS	3 <u>1</u> 32 33 34 35 35 36	0 0 0 0 0 0	0 0 5 8 0 3	1 1 7 16 3 7	0 0 3 21 1 7	1 15 45 4 17	(1%) (18%) (54%) (5%) (21%)	1% 0% 9.1% 52.5% 15.2% 22.2%
1000 40 50 55 56 73 85 87 89 90 90 97	AR AI AR AR AR AR AR AR AR		DRGIVGAHFDY TMIVVVITEHY GRFLEWLKRSY ERRITGTTEYY ITGTNWFDP GYSGYDAFDI GGSSGWYLIDY EYSSSFDY RASSFSFDY GGAHCGGDCST	YEDY WGQG1 YYDY WGQG1 YYYGHDV WGQG1 YYGHDV WGQG1 WGQG1 WGQG1 WGQG1 YYFDY WGQG1 YYFDY WGQG1	LVTVSS TVTVSS TVTVSS LVTVSS MVTVSS LVTVSS LVTSS LVALSS LVALSS LVALSS	3 <u>1</u> 32 33 34 35 35 36	0 0 0 0 0 0	0 0 5 8 0 3	1 1 7 16 3 7	0 0 3 21 1 7	1 15 45 4 17	(1%) (18%) (54%) (5%) (21%)	1% 0% 9.1% 52.5% 15.2% 22.2%
2 1000 40 40 55 55 55 55 55 55 55 55 56 73 89 90 90 90 90 90 90 102 1104	AR AI AR AG AR AR AR AR AR AR		DRGIVGAHFDY TMIVVVITEHY GRFLEWLKRSY ITGTNWFDP GYSGYDAFDI GGSSGWYLIDY EYSSSSFDY RASSFFDY GGAHCGGDCST VGATLFDY	YFDY WGQGT YFDY WGQGT YYYGHDV WGQGT YYYGHDV WGQGT WGQGT WGQGT YYFDY WGQGT YGHDV WGQGT YGHDV WGQGT Y WGQGT	LVTVSS TVTVSS TVTVSS LVTVSS LVTVSS LVTVSS LVTSS LVALSS LVTVSS LVTVSS	3 <u>1</u> 32 33 34 35 35 36	0 0 0 0 0 0	0 0 5 8 0 3	1 1 7 16 3 7	0 0 3 21 1 7	1 15 45 4 17	(1%) (18%) (54%) (5%) (21%)	0% 9.1% 52.5% 15.2% 22.2%

Human  $\mu$ -specific mRNAs were amplified by PCR, cloned and analysed by sequencing or by hybridization to V<sub>µ</sub>- and J<sub>µ</sub>-region specific probes. *a*, Nucleotide sequences of 18 unique human heavy chain clones are divided into V<sub>µ</sub>, D, J<sub>µ</sub> and N segments, as identified by homology with published germline sequences<sup>9,12,29-31</sup>. Whether each V–D–J junction is in or out of open reading frame is indicated. Each D segment assignment is based on at least 8 bases of homology. Differences from the published sequences are in lower case. N-segment nucleotides were determined by their lack of sequence homology to V<sub>µ</sub>. D or J<sub>µ</sub> sequences. Clones chosen for sequencing had previously been shown to possess a V<sub>µ</sub> segment by colony hybridization (see part c). *b*, Predicted amino acid sequences of the 14 in-frame V–D–J junctions are divided into Framework Region 3 (FR3), CDR3 and FR4<sup>14</sup>. *c*, Results of colony hybridizations showing V<sub>µ</sub> and J<sub>µ</sub> gene utilization, as compared to that detected in human peripheral B cells<sup>12</sup>. Results are given only for colonies hybridizing to V<sub>µ</sub>, J<sub>µ</sub> and Cµ probes.

> ELISA. H $\mu$  was expressed on the surface of 1.5–2.5% of the B220<sup>+</sup> cells in blood (Fig. 2*a*) or spleen (not shown) in all 5 yH1 strains analysed (2B, 2C, 3A, 5C, 125A). Approximately half of the h $\mu^+$  population had no detectable surface mouse mu (m $\mu$ ) (Fig. 2*a*), indicating that h $\mu$ production can substantially exclude the expression of m $\mu$ . H $\mu$  was detected in sera derived from all yH1 strains at 0.2–3.8  $\mu$ g ml<sup>-1</sup> (Table 1*c*). In all 3 yK1 strains examined (8.2A, 9.2C, 10.2B), 5–9% of the B220<sup>+</sup> splenocytes expressed surface h $\kappa$  (Fig. 2*b*). In >80% of this population, h $\kappa$  excluded the expression of mouse lambda (m $\lambda$ ) or kappa (m $\kappa$ ) (Fig. 2*c*,*d*). All yK1 mice derived from structurally intact YACs expressed h $\kappa$  in serum at 8–30  $\mu$ g ml<sup>-1</sup> (Table 1*d*).

Human Ig-producing (HuAb) mice containing one copy each of yH1 and yK1 were generated (Fig. 1*e*). Threecolour flow cytometry of peripheral blood lymphocytes, derived from five HuAb strains (8.2A;125A, 8.2A;5C, 8.2A;2B, 9.2C;125A, 9.2C;2B) revealed B220<sup>+</sup> populations containing 0.8–3.9% hµ<sup>+</sup> or 1.4–4.8% hK<sup>+</sup> cells (Fig. 2*e* and data not shown). Significantly, all five HuAb strains contained a population of B220<sup>+</sup> cells (0.06–0.27%) which simultaneously expressed both hµ and hK (Fig. 2*e* and legend). The production of serum antibodies in HuAb mice containing both hµ and hK (hµ/hK) was demonstrated by an ELISA in which anti-hµ antibody was used to capture and anti-h $\kappa$  antibody used to detect the product. H $\mu$ /h $\kappa$  antibodies were detected in HuAb strains 8.2A;2B and 8.2A;5C at 0.7 and 0.3  $\mu$ g ml<sup>-1</sup>, respectively (data not shown). Thus, in HuAb mice, human heavy and kappa genes on YACs were productively rearranged and expressed, leading to the presence of a significant population of B cells expressing both surface h $\mu$  and h $\kappa$ and secreting antibodies containing both human heavy and light chains in the mouse serum.

#### Diverse adult-like human Ig repertoire in mice

To determine the diversity of the hµ and h $\kappa$  repertoire in YAC-containing mice, hµ and h $\kappa$  cDNAs were cloned from mouse spleen RNA. Hybridization analysis of hµ and h $\kappa$  cDNA clones revealed broad usage of the V and J genes contained in the YACs (Tables 2*c*, 3*c*). All six J<sub>H</sub> and five J<sub> $\kappa$ </sub> segments were represented with a frequency comparable to that detected in adult human B cells<sup>12,13</sup>. Three of the four V<sub>H</sub> families in yH1 were represented, with V<sub>IV</sub> used about half as often as V<sub>VI</sub> and V<sub>I</sub>. No V<sub>II</sub> transcripts (Table 2) or V<sub>II</sub>–J<sub>H</sub> rearrangement products (data not shown) were detected, suggesting that the proximity of V<sub>II</sub> to the YAC vector cloning site may account for its inability to rearrange. All three V<sub> $\kappa$ </sub> genes were represented, with B3 more frequently used than B2 or B1 (Table 3).

To analyse further the human Ig repertoire expressed in these mice, individual cDNA clones were sequenced. The 18 h $\mu$  cDNAs analysed displayed a V<sub>H</sub> and J<sub>H</sub> usage similar to that detected by hybridization (Table 2). Ten different D regions were represented, all with significant homology to known germline D genes. Some D sequences with less than 85% identity (for example, N1 in clones µ43 and µ85, and LR2 in clones  $\mu$ 90 and  $\mu$ 97) may represent novel D segments. For example, the C to T and A to G changes observed at the same position in the D segments of µ43 and µ85 (and ref. 12), suggest the existence of a new DN family member. Multiple reading frames were used in some of the D regions (µ90/µ97, µ55/µ102, µ46/µ100), suggesting a D usage more human-like than mouse<sup>12,14</sup>. Non-germlike nucleotides (N addition) were observed in 15 (83%) of the h $\mu$  cDNAs, with a majority having N additions at both the VD and DJ junctions. The length of N addition varied between 1-12 bp (average 6.1). The majority of the in-frame clones contained a complementarity determining region 3 (CDR3) of 10-18 amino acids (average 12). The V<sub>x</sub> and J<sub>x</sub> usage observed for 21 sequenced h $\kappa$  cDNAs also agreed with hybridization analysis. In seven of the clones, N additions of 1–4 bp were found at the V–J junction. CDR3 sequences for in-frame  $\kappa$  transcripts were 9–10 amino acids in length. The J<sub> $\kappa$ </sub> usage and CDR3 length observed are consistent with previous results for human B cells<sup>13</sup>.

The pattern of  $V_H$ , D and  $J_H$  usage observed in human Ig YAC-containing mice is reminiscent of adult human B cells<sup>12,13</sup>, in contrast to human Ig minigene-bearing mice<sup>2-4</sup>. There is an absence of position-biased  $V_H$  and D usage, in particular, for the  $V_{vI}$  and DQ52 segments which are characteristic of human fetal development<sup>15,16</sup>, with the latter dominating the in-frame repertoire observed in minigene-bearing mice<sup>3,4</sup>. Furthermore, the average length of N addition (6.1 bp), and thus the CDR3 region, closely approximates that seen in adult human B cells (7.7 bp)<sup>12</sup>, while in minigene-bearing mice the average length (2.9 bp)<sup>3,4</sup> resembles that seen in adult mouse B cells (3.0 bp)<sup>17</sup>. These results suggest that the human Ig YACs contain sequences required to direct human-like repertoires in mice. Therefore, introduction of YACs

#### Table 3 Repertoire analysis of human $\kappa$ transcripts expressed in transgenic mice

lone	Fram	e V		N	J					
1010	in	B3	AGTACTCCTC		J1		GGACGTTCG	SCCAAGGGACC.	AAGGTO	GAAATCAAA
2	out	B3	AGTACTCCT	TTCT	J2		GTGCAGTTTTG	SCCAGGGGACC.	AAGCTO	GAGATCAAA
3	in	B3	AGTACTCC		J1		GTGGACGTTCG	CCAAGGGACC.	ATGGT	GAAATCAAA
.5	out	B3	TTTTCCTC		J3			CCCTGGGACC.		
.5	out	B3	AGTACTCCT		J1		GACGTTCG	SCCAAGGGACC.	AAGGTO	GAAATCAAA
(8	in	B3	AGTACTCCTC		J2		GCAGTTTTG	SCCAGGGGACC.	AAGCTO	GAGATCAAA
.9	in	B3	AGTACTT	т	J2		GTGCAGTTTTG			
10	in	B3	AGTACTCC	-	J1		GTGGACGTTCG	GCCAAGGGACC.	AAGGT	GAAATCAAA
13	out	B3	AGTACTCCTC	G	J1		GGACGTTCG	GCCAAGGGACC	AAGGT	GAAATCAAA
14	in	B3	AGTACTCC	CAT	J2		GTGCAGTTTTG	GCCAGGGGGACC	AAGCT	GAGATCAAA
15	out	B3	AGTACTCC	AT	J2		GTGCAGTTTTG			
16	out	B2	TTCCC	***	J3			GCCCTGGGAC		
18	in	B3	AGTACTCC		J4		GCTCACTTTCG	GCGGAGGGACC	AAGGT	GAGATCAAA
20	in	B2	TTCCCT		Jĺ		TGGACGTTCG	GCCAAGGGACC	AAGGT	GAAATCAAA
22	out	B2	TTCCCTC		J4		ACTTTCG	GCGGAGGGACC	AAGGT	GAGATCAAA
22 25	in	B2 B3	AGTACTCC		J3		ATTCACTTTCG	GCCCTGGGACC	AAAGT	GATATCAAA
27	in	B3	AGTACTCC		J4		GCTCACTTTCG			
28	out	B3	AGTACT	GTC	J3		TCACTTTCG	GCCCTGGGACC	AAAGT	GATATCAAA
29	in*	B3	AGTACTCC	CAT	J2		GTGCAGTTTTG	GCCAGGGGACC	TAGCT	GAGATCAAA
30	in	B1	TTTCCTC	0.111	J1		GGACGTTCG	GCCAAGGGACC	AAGGT	GAAATCAAA
31	out	B3	AGTACTCCTCC		J4			GCGGAGGGACC		
32	in	B3	AGTACTCC		J3		ATTCACTTTCG	GCCCTGGGATC	AAAGT	GGATATCAAA
		B3			J1		0010000000	GCCAAGGGACC	A A COM	~~~~~~~~~~
223							GGACGTTCG	GCCANGGGACC	WWGGT	JOHNNICHAN
<33 <34	out in	B3 B3	AGTACTCCTCC AGTACTCCTCC		51 51			GCCAAGGGACC		
34 	in	B3	AGTACTCCTCC				GACGTTCG	GCCAAGGGACC	AAGGT	GGAAATCAAA
34	in FR3	B3	AGTACTCCTCC		51 	B1	GACGTTCG	B3	Tota	1
34	IN IN IN IN IN IN IN IN IN IN IN IN IN I	CDR3 QQYYSTPRT	AGTACTCCTCC		51	4	GACGTTCG B2 13	B3 108	Tota 125	1 (47%)
34	in FR3	B3	AGTACTCCTCC		C J1 J1 J1 J2	4 10	GACGTTCG B2 13 5	<b>B3</b> 108 53	Tota 125 68	1 (47%) (26%)
34	IN IN IN IN IN IN IN IN IN IN IN IN IN I	CDR3 QQYYSTPRT	AGTACTCCTCC		51	4	GACGTTCG <b>B2</b> 13 5 2	<b>B3</b> 108 53 29	Tota 125 68 31	1 (47%) (26%) (12%)
34 	FR3 YYC YYC YYC	CDR3 QQYYSTPRT QQYYSTPRT QQYYSTPRS	AGTACTCCTCC		J1 C J1 J1 J2 J3	4 10	GACGTTCG B2 13 5	<b>B3</b> 108 53	Tota 125 68	1 (47%) (26%)
34 1000 1 3 8 9	PR3 YYC YYC YYC YYC YYC	CDR3 QQYYSTPRT QQYYSTPWT QQYYSTPRS QQYYSTLCS	AGTACTCCTCC FR4 FGQGTKVEIKR FGQGTKVEIKR FGQGTKLEIKR FGQGTKLEIKR		J1 C J1 J2 J3 J3 J4	4 10 0 1	GACGTTCG <b>B2</b> 13 5 2	<b>B3</b> 108 53 29	Tota 125 68 31	1 (47%) (26%) (12%)
34 210ne 11 33 88 59 110	FR3 YYC YYC YYC YYC YYC	CDR3 QQYYSTPRT QQYYSTPRS QQYYSTPRS QQYYSTPLCS QQYYSTPWT	AGTACTCCTCC FR4 FGQCTKVEIKR FGQCTMVEIKR FGQCTKLEIKR FGQCTKLEIKR FGQCTKVEIKR		J1 C J1 J1 J2 J3	4 10 0	GACGTTCG B2 13 5 2 9	<b>B3</b> 108 53 29 25	Tota 125 68 31 35	1 (47%) (26%) (12%) (13%)
34 1 3 8 9 10 14	FR3 YYC YYC YYC YYC YYC YYC	CDR3 QQYYSTPRT QQYYSTPRT QQYYSTPRS QQYYSTLCS QQYYSTLCS QQYYSTPWT QQYYSTPMCS	AGTACTCCTCC FR4 FGQGTKVEIKR FGQGTKVEIKR FGQGTKLEIKR FGQGTKLEIKR FGQGTKLEIKR		J1 C J1 J2 J3 J3 J4 J5	4 10 0 1 0	GACGTTCG <b>B2</b> 13 5 2 9 0	<b>B3</b> 108 53 29 25 <b>4</b>	Tota 125 68 31 35 4	1 (47%) (26%) (12%) (13%) (1%)
34 1000 11 38 99 110 114 118	PR3 YYC YYC YYC YYC YYC YYC YYC YYC	CDR3 QQYYSTPRT QQYYSTPWT QQYYSTPRS QQYYSTPRS QQYYSTPWT QQYYSTPMCS QQYYSTPMCS	AGTACTCCTCC FR4 FGQGTKVEIKR FGQGTKVEIKR FGQGTKLEIKR FGQGTKLEIKR FGQGTKLEIKR FGQGTKLEIKR FGQGTKVEIKR		J1 C J1 J2 J3 J3 J4	4 10 0 1	GACGTTCG B2 13 5 2 9	<b>B3</b> 108 53 29 25	Tota 125 68 31 35 4	1 (47%) (26%) (12%) (13%)
<b>10ne</b> 1 3 8 9 10 14 18 20	FR3 YYC YYC YYC YYC YYC YYC YYC YYC YYF	CDR3 QQYYSTPRT QQYYSTPWT QQYYSTPRS QQYYSTPLCS QQYYSTPMCS QQYYSTPLT CLQHDRFPWT	AGTACTCCTCC FR4 FGQCTKVEIKR FGQCTMVEIKR FGQCTKLEIKR FGQCTKLEIKR FGQCTKLEIKR FGQCTKLEIKR FGQCTKVEIKR FGGCTKVEIKR		J1 C J1 J2 J3 J3 J4 J5	4 10 0 1 0	GACGTTCG <b>B2</b> 13 5 2 9 0	<b>B3</b> 108 53 29 25 <b>4</b>	Tota 125 68 31 35 4	1 (47%) (26%) (12%) (13%) (1%)
<b>10ne</b> 1 3 8 9 10 14 18 20 225	FR3 YYC YYC YYC YYC YYC YYC YYC YYC YYC YY	CDR3 QQYYSTPRT QQYYSTPRT QQYYSTPWT QQYYSTPWT QQYYSTPWT QQYYSTPMT QQYYSTPHT CLQHDNFPWT CLQHDNFPWT	AGTACTCCTCC FGQCTKVEIKR FGQCTKVEIKR FGQCTKLEIKR FGQCTKLEIKR FGQCTKLEIKR FGQCTKLEIKR FGGCTKVEIKR FGGCTKVEIKR FGGCTKVEIKR FGGCTKVEIKR		J1 C J1 J2 J3 J3 J4 J5	4 10 0 1 0	GACGTTCG <b>B2</b> 13 5 2 9 0	<b>B3</b> 108 53 29 25 <b>4</b>	Tota 125 68 31 35 4	1 (47%) (26%) (12%) (13%) (1%)
34 1000 1 3 8 9 10 14 18 20 225 227	FR3 YYC YYC YYC YYC YYC YYC YYC YYC YYF YYC YYC	CDR3 QQYYSTPRT QQYYSTPWT QQYYSTPWT QQYYSTPWT QQYYSTPWT QQYYSTPPT CLQHDMFPWT QQYYSTPFT QQYYSTPFT	AGTACTCCTCC FR4 FGQGTKVEIKR FGQGTKVEIKR FGQGTKLEIKR FGQGTKVEIKR FGQGTKVEIKR FGGTKVEIKR FGGTKVEIKR FGGTKVEIKR		J1 C J1 J2 J3 J3 J4 J5	4 10 0 1 0	GACGTTCG <b>B2</b> 13 5 2 9 0	<b>B3</b> 108 53 29 25 <b>4</b>	Tota 125 68 31 35 4	1 (47%) (26%) (12%) (13%) (1%)
34 1008 1 3 8 9 10 14 18 20 25 27 30	FR3 YYC YYC YYC YYC YYC YYC YYC YYC YYC YY	CDR3 QQYYSTPRT QQYYSTPRT QQYYSTPRS QQYYSTPWT QQYYSTPMCS QQYYSTPLT CLQHDRPWT QQYYSTPLT QQYYSTPLT LQSKNPFRT	AGTACTCCTCC FQQTKVEIKR FQQGTKVEIKR FQQGTKLEIKR FQQGTKLEIKR FQQGTKLEIKR FGQGTKVEIKR FGQGTKVEIKR FGQGTKVEIKR FGQGTKVEIKR FGQGTKVEIKR FGQGTKVEIKR		J1 C J1 J2 J3 J3 J4 J5	4 10 0 1 0	GACGTTCG <b>B2</b> 13 5 2 9 0	<b>B3</b> 108 53 29 25 <b>4</b>	Tota 125 68 31 35 4	1 (47%) (26%) (12%) (13%) (1%)
34 11 3 18 39	FR3 YYC YYC YYC YYC YYC YYC YYC YYC YYF YYC YYC	CDR3 QQYYSTPRT QQYYSTPWT QQYYSTPWT QQYYSTPWT QQYYSTPWT QQYYSTPPT CLQHDMFPWT QQYYSTPFT QQYYSTPFT	AGTACTCCTCC FR4 FGQGTKVEIKR FGQGTKVEIKR FGQGTKLEIKR FGQGTKVEIKR FGQGTKVEIKR FGGTKVEIKR FGGTKVEIKR FGGTKVEIKR		J1 C J1 J2 J3 J3 J4 J5	4 10 0 1 0	GACGTTCG <b>B2</b> 13 5 2 9 0	<b>B3</b> 108 53 29 25 <b>4</b>	Tota 125 68 31 35 4	1 (47%) (26%) (12%) (13%) (1%)


mRNAs containing hC<sub>x</sub> were amplified by PCR, cloned and analysed by sequencing or by colony hybridization to V<sub>x</sub>- and J<sub>x</sub>-region specific probes. *a*, Nucleotide sequences of V–J junctions of 21 independent human  $\kappa$  clones are shown, divided into V<sub>x</sub>, J<sub>x</sub> and N segments and identified based on homology to published germline B1, B2 and B3, and J<sub>x</sub> sequences<sup>24-26</sup>. Also indicated is whether each V–J junction is in or out of an open reading frame. N-segment nucleotides were determined by their lack of sequence homology to neither V<sub>x</sub> nor J<sub>x</sub> sequences. Differences from the published sequences are in lower case. The sequences shown are those which contained a V–J joining. The one sequenced B1-containing clone lacked a translational initiation site, as described<sup>25</sup>. *b*, Predicted amino acid sequences of in-frame V–J junctions are divided into FR3, CDR3 and FR4<sup>14</sup>. *c*, Results of colony hybridizations showing V<sub>x</sub> and J<sub>x</sub> gene utilization. Results are given only for colonies hybridizing to V<sub>x</sub> and J<sub>x</sub> probes. with larger numbers of variable genes should ultimately recapitulate the diversity seen in humans.

## Ag-specific fully human mAbs from mice

To determine whether HuAb mice can mount a specific human antibody response, mice were immunized with tetanus toxin C fragment (tet C). After immunization, tet C-specific hµ and h $\kappa$  were readily detected in serum (Fig. 3a). The human origin of the tet C-specific antibodies was confirmed by using an ELISA in which tet C was used to capture and anti-hµ or anti-h $\kappa$  used to detect the bound species. Thus, upon immunization, the HuAb mice are capable of producing antigen-specific human antibodies.

To determine whether antibodies containing both human heavy and light chains were produced, splenocytes derived from tet C-immunized HuAb mice (8.2A;5C) were fused with P3X63-Ag8.653 myeloma cells, and the resulting hybridomas screened for the production of tet C-specific fully human antibodies. Analysis of 678 hybridoma culture supernatants revealed 92 hk<sup>+</sup> clones and 16 hµ<sup>+</sup> clones. Three clones were found to produce fully human mAbs specific for tet C. To confirm that all of the desired properties reside within the same antibody molecule, ELISAs were used in which either tet C was used to capture and anti-hk used to detect the bound species (Fig. 3b), or anti-hµ used to capture and anti-hk used to detect the bound species (Fig. 3c). All three clones were positive in both assays, indicating that HuAb mice,

Fig. 3 Production of tet C-specific human polyclonal (a) or monoclonal (b, c) antibodies by HuAb mice. a, Sera obtained from HuAb strain 8.2A;125A, nonimmune (🔿, 🔶) or hyperimmune to tet C (□, ■) were analysed by ELISA for tet C-specific hμ (□) and hκ (■) antibodies. Similar results were obtained from HuAB strains 8.2A;2B, 8.2A;5C and 9.2C;2B. b,c, Supernatants derived from hybridomas (42C7-■,45B5-□. 45D9-, control 37G4-�), generated by fusion of hyperimmune HuAb strain 8.2A:125A splenocytes with mouse myeloma cells, were analysed for the presence of fully (hµ/hĸ) human monoclonal



antibodies (b) and for specificity of the human antibodies to tet C (c), as detected in ELISA using tet C to capture and anti-hk to detect. The hybridoma 37G4 ( $\diamondsuit$ ), secreting a tet C-specific monoclonal antibody containing only human heavy chain was used as a control in *b*, *c*.

although containing only a small fraction of B cells coexpressing  $h\mu$  and  $h\kappa$ , can mount an antigen-specific response leading to the generation of fully human mAbs. The nature of the human repertoire associated with the tet C-specific response and the extent to which somatic mutation plays a role in the maturation of tet C-specific human antibodies is currently under investigation.

## Human YACs restore B cell and Ig production


While HuAb mice can mount an antigen-specific human antibody response, the preferential expression of mouse Ig genes suggested the potential value of their inactivation to increase the production of fully human antibodies in mice. Therefore, yH1- and yK1-expressing mice were bred with mice engineered by gene targeting to be deficient in mouse Ig production.


Initially, we examined the ability of yH1 to induce proper mouse B cell development and production of human Ig in a strain containing two functionally inactivated mouse heavy chain alleles  $(yH1;\Delta J_{H}/\Delta J_{H})$ .  $\Delta J_{\mu}/\Delta J_{\mu}$  parental mice fail to rearrange their heavy chain genes, leading to a complete absence of mature B cells and a complete block in Ig production<sup>18</sup>. In yH1; $\Delta J_{\mu}/\Delta J_{\mu}$  mice, reconstitution of mature B cells (B220<sup>+</sup>,  $h\mu^+$ ) was observed in bone marrow (Fig. 4a), spleen and blood (Fig. 4e) corresponding to 58%, 55% and 30% of the levels in wildtype mice, respectively. The majority of B220<sup>+</sup>/hµ<sup>+</sup> cells in blood also expressed human delta (h $\delta$ ) and all of the h $\delta^+$ cells co-expressed h $\mu$  (data not shown), indicating proper expression and regulation of the human constant regions in these mice<sup>19</sup>. Remarkably,  $yH1;\Delta J_{\mu}/\Delta J_{\mu}$  mice produced serum hµ at 350 µg ml-1, a level 510-föld greater than parental 125A mice (Table 1c) and within 2-3-fold of normal human IgM serum levels. Huserum titres showed an age-dependent increase (not shown). These results demonstrate that yH1 can reconstitute B cell development in mice deficient in mouse heavy chains and direct the expression and assembly of high levels of hµ/mouse light chain antibodies.

The yH1; $\Delta J_{H}/\Delta J_{H}$  mice were further evaluated by analysing the orderly differentiation of bone marrowderived B cells by flow cytometry using antibodies to the cell surface marker CD43, which defines early B cell subpopulations<sup>20</sup>, in conjunction with antibodies to B220 and hµ. Bone marrow from  $\Delta J_{\mu}/\Delta J_{\mu}$  mice contained no mature B cells (B220<sup>bright/dull</sup>, CD43-; R1, R2 populations) and a population (5.5%) of pro-B cells (B220<sup>dull</sup>, CD43+; R3 population), comparable to wild-type mice (Fig. 4*a*). In contrast,  $yH1;\Delta J_{H}/\Delta J_{H}$  bone marrow contained a nearly normal R1, R2 population (41%) of mature B cells; however, the size of the pro-B cell population (12.4%) was increased (Fig. 4a). Surface hµ was detected only in the B220<sup>+</sup>, CD43<sup>-</sup> population of yH1; $\Delta J_{H}/\Delta J_{H}$  mice, similar to m $\mu$  in wild-type mice (Fig. 4b). Thus, while B cell development and Ig production are substantially restored in yH1; $\Delta J_{\mu}/\Delta J_{\mu}$  mice, the maturation of bone marrowderived B cells may be somewhat less efficient than in normal mice.

To delineate this partial block in B cell maturation, we examined the surface expression of HSA and BP-1 in bone marrow to resolve the pro-B and pre-B cell populations<sup>20</sup>. Large, primarily CD43<sup>-</sup> populations of B220<sup>+</sup>, HSA<sup>+</sup> cells and B220<sup>+</sup>, BP-1<sup>-</sup> cells as well as a smaller CD43<sup>-</sup>, B220<sup>+</sup>, BP-1<sup>+</sup> cell population confirmed that B cell development is largely normal in these mice (Fig. 4*c*,*d*). However,







populations (R1, R2 and R3 (high (bright) or low (dull) levels of surface B220<sup>+</sup> are delineated)) are indicated with their respective percentages of positively stained cells. e, Peripheral blood (E1, E2) and spleen (E3) lymphocytes were assayed for hm and B220 in  $\Delta J_{H}/\Delta J_{H}$  (E1) and in yH1; $\Delta J_{H}/\Delta J_{H}$  mice (E2, E3). The net percentage of positively-stained cells is shown in each quadrant. In the normal 129×B6 mouse, 64% of the cells in blood and spleen were B220<sup>+</sup>. All animals used were 3 month old males.

increased populations of CD43<sup>+</sup>, HSA<sup>+</sup> cells and CD43<sup>+</sup>, BP-1<sup>-</sup> cells as well as smaller populations of CD43<sup>+</sup>, HSA<sup>-</sup> cells and brighter CD43<sup>-</sup>, HSA<sup>+</sup> cell populations indicated a small accumulation of pro-B cells, suggesting a less efficient pro-B cell to pre-B cell transition, the stage at which V to DJ joining occurs<sup>20</sup>.

We next evaluated the ability of yH1 and yK1 together to restore B cell development and Ig production in a strain called Xenomouse, which also contains two functionally inactivated mouse heavy and kappa light chain alleles  $(yK1;yH1;\Delta J_{H}/\Delta J_{H};\Delta C_{L}/\Delta C_{\kappa})$ . In the  $\Delta J_{H}/\Delta J_{H};\Delta C_{L}/\Delta C_{\kappa}$  parental mouse, called DI (for double-inactivated), the expression of both mouse heavy and  $\kappa$  was blocked (manuscript in preparation). In contrast to DI mice which did not produce any mature B220<sup>+</sup> cells (Fig. 5a1-c1), mature B220<sup>+</sup> cells were present in Xenomouse at 10% of the level seen in the wild-type. Approximately half of these cells (43%) co-expressed h $\mu$  and h $\kappa$ , while the remainder (57%) co-expressed hµ and m $\lambda$  (Fig. 5a2, b2). No coexpression of  $m\lambda$  and  $h\kappa$  was detected, indicating that each light chain completely excluded the expression of the other (Fig. 5c2). Higher levels of fully human hµ/hĸ antibodies (10  $\mu g$  m<sup>1-1</sup>) than h $\mu/m\lambda$  antibodies (3  $\mu g$  m<sup>1-1</sup>) were detected in Xenomouse. The level of hµ/hk was at least several hundredfold higher than the level detected in the parental HuAbstrain (9.2C;2B), confirming that inactivation of the mouse heavy and  $\kappa$  genes greatly increased levels of fully human antibodies. In addition, the relative level of B cells expressing only hµ and hk in Xenomouse was 100-200-fold higher than in the HuAb strains from which antigen-specific human antibodies were obtained, suggesting the usefulness of Xenomouse in deriving fully human mAbs. Higher levels of hµ/hk antibodies (200 µg ml<sup>-1</sup>) were detected in another Xenomouse strain (8.2A; 2B;  $\Delta J_{H}/\Delta J_{H}$ ;  $\Delta C_{r}/\Delta C_{r}$ ). As HuAb strains producing higher levels of h $\mu$ /h $\kappa$  are bred with DI mice to create additional Xenomouse strains, it is anticipated that higher levels of B cell reconstitution and antibody production will be attained.

#### Discussion

We have produced antigen-specific, fully human mAbs in mice and created mouse strains in which the majority of antibodies produced are fully human. The ability to derive antigen-specific human antibodies upon immunization of mice may be related to the diverse human adult-like repertoire observed following the introduction of large, intact germline segments of the human heavy and  $\kappa$  loci contained on YACs, in contrast to the abnormal repertoires seen in human Ig minigene-bearing mice<sup>2-4</sup>. While the human Ig repertoire of our YAC-containing mice are characterized by the V, D and J usage, length of N addition and CDR3 size observed for adult human B cells<sup>12,13</sup>, earlier studies with minigenes revealed fetal-like, positionbiased usage of D segments and abnormally small N addition and CDR3 size<sup>3,4</sup>, and abnormal CDR3 sequences<sup>2</sup>. These differences, as well as the higher, less position-dependent expression levels noted for YACcontaining mice, may reflect the greater size, variable gene content, structural integrity upon integration, and/or presence of unidentified regulatory elements needed for optimal expression and proper regulation.

The possibility that human Iggenes compete inefficiently with mouse antibody genes by virtue of intrinsic activity or fewer V segments, led us to investigate human Ig expression in mice with inactivated mouse Ig genes. Together, human heavy and  $\kappa$  YACs restored B cell development in mice with inactivated mouse heavy and  $\kappa$ genes, and the majority of antibodies produced are fully human. Indeed, as half of the mature B cells of these mice




Fig. 5 Reconstitution of B cell development in Xenomouse. Peripheral blood mononuclear cells derived from a 3.5 week old DI ( $\Delta J_{\mu}/\Delta J_{\mu}$ ;  $\Delta C_{\mu}/\Delta C_{\nu}$ ) mouse (A1, B1, C1) or Xenomouse (9.2C; 2B;  $\Delta J_{\mu}/\Delta J_{\mu}$ ;  $\Delta C_{\mu}/\Delta C_{\nu}$ ) (A2, B2, C2) were assayed for hµ and h<sub>x</sub>(a), hµ and m $\lambda$  (b) or hk and m $\lambda$  (c) as described in Methodology. The net percentage of positively stained cells is shown in each quadrant. All hµ<sup>+</sup>, hk<sup>+</sup> and hµ<sup>+</sup>, m\lambda<sup>+</sup> cells were B220<sup>+</sup>. In the normal mouse, 47% of peripheral blood mononuclear cells were B220<sup>+</sup>. DI mice were generated by the breeding of homozygous  $\Delta J_{\mu^-}$  mutant ( $\Delta J_{\mu}/\Delta J_{\mu}$ ) mice<sup>18</sup> and homozygous  $\Delta C_{\kappa}$ -mutant ( $\Delta C_{\mu}/\Delta C_{\mu}$ ) mice.  $\Delta C_{\mu}/\Delta C_{\kappa}$  mice were derived by gene-targeted deletion of the mouse  $C_{\kappa}$  region (manuscript in preparation.)

express surface hµ and h $\kappa$ , but not m $\lambda$ , and the relative level of hµ/h $\kappa$  B cells is at least 100-fold higher than in HuAb strains used to derive antigen-specific human antibodies, such mice should be extremely useful for obtaining human monoclonal antibodies upon immunization. The yH1 YAC induced the maturation of the growth-arrested B cell lineage in homozygous  $\Delta J_{H^{-}}$ mutant mice, leading to the production of hµ levels approaching those in normal human serum. These results suggest that hµ can readily assemble with mouse B cell receptors, allowing the efficient development of mature, functional B cells. The analysis of bone marrow-derived B cells suggests that in yH1; $\Delta J_{H}/\Delta J_{H}$  mice the progression of late pro-B to pre-B cells is somewhat less efficient than in normal mice, a point at which V-DJ rearrangement is initiated<sup>20</sup>. The limited number of V genes in yH1 may result in a lower frequency of rearrangement and thus incomplete B cell development (analysis in progress), suggesting the value of a greater number of human V genes to support more complete B cell maturation and the generation of even more complex repertoires.

The ability to produce a diverse repertoire of fully human monoclonal antibodies may have significant application to human therapy. Unlike humanized mouse antibodies which contain a significant number of residues from murine hypervariable regions, fully human antibodies may be less immunogenic, and thus more suited for repeated administration, as they would present only minor idiotypic variations from any given patient. Such mice lack immunological tolerance to and thus readily yield antibodies to human proteins, which may constitute an important class of therapeutic targets. The introduction of larger portions of the human heavy and light chain loci may ultimately yield strains of mice capable of recapitulating the full repertoire characteristic of the human humoral response to infection or immunization. This strategy of introducing large segments of the human genome into mice coupled with inactivation of the corresponding mouse genes may also have applicability to the investigation of other complex or uncharacterized loci.

Note added in proof: Hybridomas producing human antibodies against a human protein, IgE antibody, have been generated.

### Methodology

**Generation and DNA analysis of yH1- and yK1-containing ES cells and mice.** yH1 (240 kb) and yK1 (195 kb) were identified from the Washington U. human-YAC library DNA using  $V_{v1}$  PCR primers and  $a_v$  probe, respectively (M.J.M. *et al.*, manuscriptin preparation). yH1- and yK1-containing yeast were fused with E14.TG3B1 cells as described' and HAT-resistant colonies were expanded for analysis. Probes used: D (detecting three expected *Hind*III bands, 9.7 kb, 8.5 kb and 7.0 kb (as a doublet), of D1–D4 family segments), Cµ, C&, J<sub>µ</sub>,  $V_{v1}$ ,  $V_{1}$  and  $V_{1v}$  as described in ref. 21;  $V_{11}^{22}$ ,  $C_{k}$  (ATCC, 59173),  $J_{s}^{2324}$ , B1<sup>25</sup>, B2<sup>25</sup>, B3<sup>26</sup>, mC<sub>k</sub><sup>27</sup> and yeast Ty<sup>7</sup>. The number of integrated YACs per ES cell was determined by densitometric measurements of human Ig hybridization signals, normalized to those of mouse  $C_{k}$ probe, and compared to the signal intensity of YACs in yeast. An equivalent hybridization signal should be obtained from a singlecopy sequence in 20 ng of haploid yeast DNA and in 10 µg of diploid mammalian DNA.

Chimaeric mice were generated by microinjection of ES cells into C57Bl/6 blastocysts. HuAb offspring were identified by PCR analysis of tail DNA (30 cycles of 1 min at 94 °C; 2 min at 60 °C; 3 min at 72 °C) using human-specific primers for D: (DXPA: 5'-GCAATTACTAGTATAGACCCGAGTGTCCCC-3'; and DXPB: 5'-GCAATGGTCGACGGTTTTTGATGGACTCTG-3'; 230 bp fragment), and J<sub>x</sub>: (J<sub>x</sub>0: 5'-CTCGAAAAGGGAGTTGAGCT TCAGCAGCTG-3'; and J<sub>x</sub>3: 5'-GATACAATGGCACTAAAATC TCACG-3'; 860 bp fragment) and control primers for the mouse  $\gamma$  interferon receptor (IFN- $\gamma$ R) (5'-TTGGATGCTGTGGTGGTGCTC-3' and 5'-GACCTATTTGTGAATGGAAGC-3'; 550 bp fragment). The size markers (M) are a 1 kb DNA ladder (Gibco/BRL).

Flow cytometry analysis. Peripheral blood, spleen and bone marrow lymphocytes obtained from 4-12 week old transgenic or control mice were purified on Lympholyte M (Accurate) and treated with purified Fc y II receptor (Pharmingen, 01241D) to block nonspecific binding to Fc receptors, stained with antibodies and analysed on a FACScan (Becton Dickinson, LYSIS II software). Antibodies used: CyChrome anti-B220 (Pharmingen, 01124A); fluorscein isothiocyanate (FITC) anti-hIgM (Pharmingen, 08074D); phycoerythrin (PE) anti-mIgM\* (Pharmingen, 05095B) and PE antimIgM<sup>b</sup> (Pharmingen, 05105B); biotin anti-ho (Southern Biotechnology Association, 9030-08); biotin anti-hk (Pharmingen, 08172D); FITC anti-mλ (Pharmingen, 02174D); FITC anti-CD43 (Pharmingen, 01604D); PE anti-CD43 (Pharmingen, 01605B); biotin anti-6C3/BP-1 (Pharmingen, 01282D); PE anti-HSA (Pharmingen, 01575A). PE-streptavidin (Pharmingen, 13025D) was used to detect biotinvlated antibodies.

To assay h $\kappa$  versus m $\kappa$  expression in yK1 transgenic mice, mouse peripheral blood lymphocytes were first incubated with rat IgG (Pierce, 31233) then stained with PE-conjugated goat anti-m $\kappa$ (Southern Biotechnology Association, 1050-09), washed, incubated with mouse IgG (Pierce, 31204), then stained with FITC-conjugated mouse anti-h $\kappa$  (Pharmingen, 08174D) and CyChrome-conjugated anti-B220.

ELISA assays. Sera were obtained from 4–12 wk old transgenic or chimaeric (containing 40–90% of ES cell-derived B cells) mice. Human serum  $\mu$  was assayed using mouse monoclonal anti-h $\mu$ (AMAC, Clone Af6) immobilized on Nunc Immuno plates (Maxisorp F96) and detected with biotinylated goat anti-h $\mu$ (Caltag, preabsorbed with normal mouse serum to lower background due to cross reactivity). Similarly, h $\kappa$  was assayed using goat anti-h $\kappa$  (Vector) to capture and detected with biotinylated goat anti-h $\kappa$  (Vector). The standard used to determine h $\mu$  concentrations was hIgM (Sigma, I-



8260) shown to be equivalent to a chimaeric hIgM/m $\lambda$  antibody (Serotec, MCA 446). The standard used to determine hk concentrations was hIgG<sub>1</sub>/hk (Sigma, I-3889). Hµ/hk antibodies were detected in serum by ELISA using mouse monoclonal anti-hµ (AMAC, Clone Af6) to capture and detected with biotinylated goat anti-hk (Vector) using hIgM (Sigma, I-8260) as a standard. Tet C-specific antibodies (polyclonal or monoclonal) were assayed by coating plates (see above) with 100 ng tet C (Boehringer Mannheim, 1348655)/well, incubating with serial dilutions of the appropriate serum and then detecting with either biotinylated goat anti-hµ (Caltag, see above) or biotinylated goat anti-hk (Vector). Human monoclonal antibodies were assayed the same as hµ/hk antibodies above. Biotinylated antibodies were detected using ABC-HRP (Vector, PK-4000). Absorbance at A490 was measured using a UVmax spectrophotometer .

Immunization of mice and generation of hybridomas. Mice were immunized 4 times at about 2 wk intervals with tet C (Boehringer Mannheim 1348655) 50 µg/injection, in Freund's Complete Adjuvent (primary injection) or Freund's Incomplete Adjuvent (subsequent boosts) subcutaneously. The mice were bled 4 days after final boost and titered for human anti-tet C antibodies by plate ELISA. Serially diluted samples were incubated with 100 ng tet C bound/well of Nunc Immuno plate. The human antibody chains were then detected using the biotinylated anti-hµ and h $\kappa$  antibodies (see "ELISA assays"). To generate mouse hybridomas, splenocytes from immunized mice were fused with nonproducer P3X63-Ag8.653 myeloma cells, 4–5 days following the final boost, using 50% PEG 4000 (Boehringer Mannheim). After 10–14 days the supernatants from hybrids growing in HAT-selected medium were screened for the presence of fully human antibodies and for tet C specificity as described above .

Repertoire of human Ig transcripts expressed in transgenic mice. poly(A)<sup>+</sup> mRNA was isolated from a yH1 spleen (strain 2B) or a yK1 spleen (strain 8.2A) transgenic mouse using a FastTrack kit (Invitrogen). Human  $\mu$ -specific mRNAs amplified using a 5' Amplifinder RACE kit (Clontech), using oligonucleotide h $\mu$ P1 (5'–

#### Received 20 December; accepted 17 March 1994.

- Brüggemann, M. et al. A repertoire of monocional antibodies with human heavy chains from transgenic mice. Proc. natn. Acad. Sci. U.S.A. 86, 6709– 6713 (1989).
- Brüggemann, M. et al. Human antibody production in transgenic mice: expression from 100 kb of the human IgH locus. *Eur. J. Immunol.* 27, 1323– 1326 (1991).
- Taylor, L.D. et al. A transgenic mouse that expresses a diversity of human sequence heavy and light chain immunoglobulins. Nucl. Acids Res. 20, 6287–6295 (1992).
- Tuaillon, N., Taylor, L.D., Lonberg, N., Tucker, P.W. & Capra, J.D. Human immunoglobulin heavy-chain minilocus recombination in transgenic mice: Gene-segment use in μ and γ transcripts. *Proc. natn. Acad. Sci. U.S.A.* 90, 3720–3724 (1993).
- Choi, T.K. et al. Transgenic mice containing a human heavy chain immunoglobulin gene fragment cloned in a yeast artificial chromosome. *Nature Genet.* 4, 117–123 (1993).
- Davies, N.P. et al. Creation of mice expressing human antibody light chains by introduction of a yeast artificial chromosome containing the core region of the human immunoglobulin k locus. *Bio/Technology* 11, 911–914 (1993).
  Jakobovits, A. et al. Germ-line transmission and expression of a humantion of the human immunoglobulin k locus. *Bio/Technology* 11, 911–914 (1993).
- Jakobovits, A. et al. Germ-line transmission and expression of a humar derived yeast artificial chromosome. Nature 362, 255–258 (1993).
- Shin, E.K. et al. Physical map of the 3' region of the human immunoglobulin heavy chain locus: clustering of autoantibody-related variable segments in one haplotype. EMBO J. 10, 3641–3645 (1991).
- Matsuda, F. et al. Structure and physical map of 64 variable segments in the 3 '0.8-megabase region of the human immunoglobulin heavy-chain locus. Nature Genetics 3, 88-94 (1993).
- Weichhold, G.M, Ohnheiser, R. & Zachau, H.G. The human immunoglobulin κ locus consists of two copies that are organized in opposite polarity. *Genomics* 16, 503–511 (1993).
- Reid, L., Gregg, R.G., Smithies, O. & Koller, B.H. Regulatory elements in the introns of the human HPRT gene are necessary for its expression in embryonic stem cells. *Proc. natn. Acad. Sci. U.S.A.* 87, 4299–4303 (1990).
  Yamada, M. *et al.* Preferential utilization of specific immunoglobulin heavy
- Yamada, M. *et al.* Preferential utilization of specific immunoglobulin heavy chain diversity and joining segments in adult human peripheral blood B lymphocytes. *J. exp. Med.* **173**, 395–407 (1991).
- Marks, J.D., Tristem, M., Karpas, A. & Winter, G. Oligonucleotide primers for polymerase chain reaction amplification of human immunoglobulin variable genes and design of family-specific oligonucleotide probes. *Eur. J. Immunol.* 21, 985–991 (1991).
- Kabat, E.A., Wu, T.T., Perry, H.M. Gotternan, K.S. & Foeller, C. Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH publication No. 91, 3242 (1991).
- Schroeder, H.W., Jr. & Wang, J.Y. Preferential utilization of conserved immunoglobulin heavy chain variable gene segments during human fetal life. *Proc. natn. Acad. Sci. U.S.A.* 87, 6146–6150 (1990).
- 16. Cuisinier, A.-M., Guiguo, V., Boubli, L., Fougereau, M. & Tonnelle, C.

amplification. Human K-specific cDNAs were amplified using hKP1 (5'-CTCTGTGACACTCTCCTGGGAGTT-3') for reverse transcription and hKP2 (5'-ACCCGATTGGAGGGCGTT-ATCCAC-3') for amplification. PCR products were cloned into pCRII using a TA Cloning kit (Invitrogen) and their sequences determined by double-stranded dideoxynucleotide sequencing. For hybridization experiments, individual colonies were picked onto multiple gridded LB-amp plates and grown at 37 °C. Colonies were transferred to Genescreen (DuPont) and lysed in situ28 to yield replicas of the ordered grid. DNAs immobilized on filters were probed with 32P-labelled V<sub>41</sub> or Cµ fragments for yH1 cDNAs or with  $V_{k}$  fragments for yK1 cDNAs (see above). <sup>32</sup>P-end labelled  $J_{H}$ - or  $J_{k}$ specific oligonucleotides were hybridized to DNAs on filters in 1% bovine serum albumin, 1.25 mM EDTA, 0.5 M NaPO, buffer, pH 7.2, and 7.1% SDS at 38 °C except J<sub>H</sub>6 which was hybridized at 30 °C. Filters were washed three times in 6× SSC for 3 min at room temperature then washed once in 6× SSC for 3 min at 34 °C with the exceptions that  $J_{\rm H}6\mbox{-}{\rm probed}$  filters were washed at 30 °C and  $J_{\rm H}5\mbox{-}{\rm exceptions}$ probed filters were washed at 42 °C.  $J_{\mu}$ -specific oligonucleotides were:  $J_{\mu}$ 1:5'-ACTTCCAGCACTGGG-3'  $J_{\mu}$ 2:5'-ACTTCGATCTCT GG-3'  $J_{\mu}$ 3:5'-TTTTGATATCTGGGG-3'  $J_{\mu}$ 4:5'-TTTGACTACT-GGGGC-3'  $J_{\mu}$ 5:5'-TTCGACCCCTGGGGC-3'  $J_{\mu}$ 6:5'-TACTA-CTACTACTAC-3'.  $J_{\kappa}$ -specific oligonucleotides were:  $J_{\kappa}$ 1: 5'-AGGTGGAAATCAAAC-3' J\_2: 5'-TTTGGCCAGGGGACC-3' J\_3: 5'-TTCGGCCCTGGGACC-3' J\_4: 5'-TTTCGGCGGAGGGAC-3' J\_5: 5'-AGGGACACGACTGGA-3'. Acknowledgements

TITTCTTTGTTGCCGTTGGGGTGC-3') for reverse transcription

and hµP2 (5'-GGGAAGCCCCGGGTGCTGCTGATG-3') for

We thank R. Kucherlapati, S. Sherwin, G. Otten, K. Rajewsky, R. Germain, R. Tepper, Y. Nishi, T. Chuman, J. Hyde, K. Lentine, G. Lee, R. Ludovico, D. Villanueva, D. Casentini-Boroz and V. Lubeck for their help and contribution to this work. This work was supported in part by Xenotech, Inc., the joint venture between Cell Genesys, Inc. and JT Immunotech.

Preferential expression of V<sub>n</sub>5 and V<sub>n</sub>6 immunoglobulin genes in early human B-cell ontogeny. Scand. J. Immunol. **30**, 493–497 (1989). Feeney, A.J. Lack of N regions in fetal and neonatal mouse immunoglobulin

- Feeney, A.J. Lack of N regions in fetal and neonatal mouse immunoglobulin V-D-J junctional sequences. J. exp. Med. 172, 1377–1390 (1990).
- Jakobovits, A. et al. Analysis of homozygous mutant chimeric mice: Deletion of the immunoglobulin heavy-chain joining region blocks B-cell development and antibody production. Proc. natn. Acad. Sci. U.S.A. 90, 2551–2555 (1993).
- Abney, E.R., Cooper, M.D., Kearney, J.F., Lawton, A.R. & Parkhouse, R.M.E. Sequential expression of immunoglobulin on developing mouse B lymphocytes: a systematic survey that suggests a model for the generation of immunoglobulin isotype diversity. *J. Immunol.* **120**, 2041–2049 (1987).
  Hardy R.R., Condie, C.E., Shinton, S.A., Kemp, J.D. & Hayakawa, K.
- Hardy R.R., Condie, C.E., Shinton, S.A., Kemp, J.D. & Hayakawa, K. Resolution and characterization of pro-B and pre-pro-B cell stages in normal bone marrow. J. exp. Med. 173, 1213–1225.
- Berman, J.E. et al. Content and organization of the human Ig V<sub>H</sub> locus: definition of three new V<sub>H</sub> families and linkage to the Ig C<sub>H</sub> locus. EMBO J. 7, 727–738 (1988).
- Takahashi, N., Noma, T. & Honjo, T. Rearranged immunoglobulin heavy chain varible region (V<sub>µ</sub>) pseudogene that deletes the second complementarity-determining region. *Proc. natn. Acad. Sci. U.S.A.* 81, 5194–5198 (1984).
- Lorenz, W., Straubinger, B. & Zachau, G.G. Physical map of the human immunoglobulin κ locus and its implications for the mechanisms of V<sub>x</sub> - J<sub>y</sub> rearrangement. *Nucl. Acids Res.* 15, 9667–9676 (1987).
- Hieter, P.A., Maizel, V.J., Jr. & Leder, P. Evolution of human immunoglobulin x J region genes. J. biol. Chem. 257, 1516–1522 (1982).
  Lorenz, W., Schäble, K.F., Thiebe, R., Stavneser, J. & Zachau, H.G. The J.
- Lorenz, W., Schäble, K.F., Thiebe, R., Stavneser, J. & Zachau, H.G. The J proximal region of the human k locus contains three uncommon V genes which are arranged in opposite transcriptional polarities. *Molec. Immunol.* 25, 479–484 (1988).
- Klobeck, H.-G., Combriato, G. & Zachau, H.G. The V-J intergenic region of the human κ locus. *Biol. Chem.* **370**, 1007–1012 (1989).
  Neumaier, P.S. & Zachau, H.G. Nucleotide sequence of a region downstream
- Neumaier, P.S. & Zachau, H.G. Nucleotide sequence of a region downstream of the mouse C<sub>e</sub> immunoglobulin gene. *Nucl. Acids Res.* 11, 3631–3636 (1983).
- Sambrook, J., Fritsch, E. F. & Maniatis, J.(eds) Molecular Cloning, A Laboratory Manual (Cold Spring Harbor Laboratory Press, New York, 1989).
  Ichihara, Y., Matsuoka, H. & Kurosawa, Y. Organization of human
- Ichihara, Y., Matsuoka, H. & Kurosawa, Y. Organization of human immunoglobulin heavy chain diversity gene loci. *EMBO J.* 7, 4141–4150 (1988).
- Flanagan, J.G. & Rabbitts, T.H. The sequence of a human immunoglobulin epsilon heavy chain constant gene, and evidence for three non-allelic genes. EMBO J. 1, 655–660 (1982).
- Ravetch, J.V., Siebenlist, U., Korsmeyer, S., Waldmann, T. & Leder, P. Structure of the human immunogloblin µ locus: Characterization of embryonic and rearranged J and D genes. Cell 27, 583–591 (1981).